The central nervous system (CNS) has a dedicated network of blood vessels to support the physiological activity of the brain, spinal cord and meninges. Consequently, inflammation of CNS vasculature can have devastating effects on neurological function.
Abstract:
The central nervous system (CNS) has a dedicated network of blood vessels to support the physiological activity of the brain, spinal cord and meninges. Consequently, inflammation of CNS vasculature can have devastating effects on neurological function.
A lack of understanding regarding the molecular pathology of CNS vasculitis impedes the development of better diagnostics and effective therapies. Here, we analyze the proteome of cerebrospinal fluid from patients with biopsy-confirmed Primary Angiitis of the Central Nervous System (PACNS) relative to non-inflammatory control patients and patients with Reversible Cerebral Vasoconstrictive Syndrome (RCVS), a syndrome that clinically mimics PACNS in several aspects. In PACNS, we find significant elevation of apolipoproteins, immunoglobulins and complement cascade components. Notably, we find a bias towards activation of the alternative complement pathway with elevated levels of the terminal cascade component, complement C5. Given the recent treatment successes of Anti-Neutrophil Cytoplasmic Antibody (ANCA) vasculitis with the C5 receptor inhibitor, CCX168 (Avacopan), our results suggest that complement C5 inhibitors may also prove useful as therapeutic interventions for PACNS.
Introduction:
The molecular basis of blood vessel inflammation, or vasculitis (also referred to as angiitis), is poorly understood. This gap in knowledge is exemplified by Primary Angiitis of the Central Nervous System (PACNS), an inflammatory disease affecting the blood vessel walls in the brain, spinal cord and meninges 1 . Without treatment, PACNS is frequently progressive and fatal. While PACNS usually presents in adulthood, it can also occur in children 2, 3 . Treatment paradigms utilizing broad immunosuppressants including corticosteroids, cyclophosphamide, and mycophenolate mofetil, based largely on the results of therapeutic trials of various types of systemic vasculitis, have been adapted for use in PACNS. While these treatments have improved the outcome of PACNS, they have adverse side-effects, and nearly half of patients relapse 4 . A lack of basic research in this area remains an obstacle for improving PACNS therapeutics and served as the motivation for this study. with biopsy-proven PACNS ( Figure 1A -F).
The majority of our biopsy-proven PACNS patients were refractory to initial treatment strategies or required continual immunosuppression to achieve remission (Supplemental File S1). These observations reflect the chronicity of inflammation of the cerebral vasculature, which is a distinguishing feature of PACNS pathophysiology 10 .
However, a straightforward analysis of PACNS CSF for molecular correlates of chronic inflammation is complicated by non-specific, acute cerebrovascular pathologies. For this reason, we analyzed an RCVS patient cohort, in addition to a set of NIC patients (Supplemental File S1). RCVS mimics some aspects of PACNS but exhibits only acute blood vessel constriction 8 . By directly comparing PACNS and RCVS patients, we sought to identify the molecule(s) or molecular pathways that contribute to the chronic inflammatory processes that define PACNS specific pathology. To determine whether the altered proteins we identified in PACNS were due solely to blood brain barrier damage we utilized data from our RCVS patients. When compared to NIC controls, we found the correlates of acute blood vessel damage, including acute Carboxypeptidase N subunit 2 (CPN2), C5, C8, and C9) that occur in PACNS are independent of the non-inflammatory, cerebrovascular injury seen in RCVS. From these findings, we conclude that PACNS pathophysiology exhibits elements of damage to blood brain barrier but also exhibits specific changes in the complement cascade, apolipoproteins and immunoglobulins that cannot be explained by acute blood brain barrier damage alone.
Mass Spectrometry analysis of CSF from NIC, RCVS and PACNS.
As indicated above, apolipoproteins, specifically ApolipoproteinB100 (ApoB100) and and Proteinase 3 (PRTN3, or PR3), two previously described antigens in ANCA associated vasculitis [13] [14] [15] [16] . These ANCA-associated antigens are expressed in the granules of neutrophils and monocytes and have ascribed roles in active inflammation. Similar to PACNS, ANCA-associated vasculitis exhibits chronic inflammation and destruction of blood vessel walls, however, the disease more frequently targets the kidney, gastrointestinal tract and lungs, rather than the CNS 17 . As described earlier, all our PACNS patients' serum ANCA antibody test was negative and none of our patients' vasculitis was identified by routine clinical testing to involve organs outside the CNS. Thus, we speculate that elevated levels of MPO and PRTN3 may be present in both types of vasculitis; however, the secondary antibody response to these proteins may manifest only in the context of systemic inflammation (i.e., ANCA-associated vasculitis).
The "Complement Phenotype" of PACNS. Deregulation of the complement cascade pathway in PACNS is the most robust and clinically significant molecular finding of this study. These findings are highly reproducible across PACNS patients, constituting a "Complement Phenotype," which predicts a hyperactive alternative complement pathway and elevated signaling through the terminal cascade ( Figure 3 ).
The complement cascade is comprised of two separate pathways, the Classical Pathway (homologous to Lectin Pathway) and the Alternative Pathway 18 . These pathways are molecularly unique at the level of the complement C3 (C3) and C5 convertases that drive cleavage of C3 and C5, respectively. In PACNS CSF, the bias towards activation of the alternative pathway is largely driven by elevated protein levels of CFP (properdin), the only known fluid phase positive regulator of the alternative pathway 19 . More specifically, CFP stabilizes the alternative pathway convertases, which are otherwise extremely unstable and easily deactivated. The bias towards the alternative pathway is also evident in the elevated protein levels of C4BPA and C4BPB, well-studied inactivators of the classical pathway specific C3 convertases 20 . Altogether, there appears to be concomitant activation of alternative pathway specific C3 and C5 convertases and inhibition of classical pathway C3 convertases. Thus, net activity favors the alternative pathway over the classical pathway.
Downstream of the alternative pathway, we observed evidence of an increase in C5, elevated protein levels of the MAC complex (C8A, C8B, C9) and a reduction in CD59, an inhibitor of the MAC complex 18 . Taken Values are plotted on a log scale, vertical line denotes an abundance of 2 normalized spectral counts to highlight minimally expressed proteins (abundance < 2 normalized spectral counts). Note the robust increase in abundance for a specific subset of proteins within the complement cascade that normally have minimal to no expression in NIC. Differential expression was evaluated using DESeq2 and t-test (see Materials and Methods), with significance defined as having fold change >1.5 and BH-adjusted p <0.05 for both tests. Asterisk denotes proteins that do not meet criteria for statistical significance but are of clinical interest. Figure 2 is overlaid onto the complement cascade pathway (adapted from KEGG, hsa04610). The fold change in protein abundance between PACNS and NIC was evaluated for all proteins annotated in the pathway. Proteins are reported as Elevated (red, >1.5 fold significant increase in PACNS), Unchanged (pink, not significantly changed in PACNS), Decreased (blue, >1.5 fold significant reduction in PACNS) or Not Observed (white, no abundance in NIC or PACNS). The prediction for C3 and C5 convertase activity (Activated, yellow; Inhibited, gray) is informed specifically by molecular changes observed in the complement regulatory proteins CFP, C4BP, CD59 and CD55. The proposed model predicts a shift towards activation of the alternative pathway (CFP, CD55), active inhibition of Classical Pathway (C4BPA and C4BPB) and elevated signaling from the terminal cascade (CD59). 
